Comparative effectiveness of combined biologic agents versus standard therapies in the treatment of plaque psoriasis: a retrospective analysis

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Sept. 18, 2024

Introduction Plaque psoriasis is a persistent skin disorder that necessitates efficient management. This study investigates the therapeutic effectiveness and timeline for lesion resolution in plaque patients treated with combined biologic agents compared to standard therapies. Methods Conducted retrospectively between March 2020 2023, included 162 moderate severe psoriasis. Participants were divided into two groups: Control Group, which received treatments, Combined Biologic Agent additional therapy secukinumab. Group while those treatments plus Results The results showed experienced significantly faster onset of effects, an average time 3.04 ± 2.25 days 6.12 2.06 Group. Additionally, occurred more rapidly agent group (7.04 2.13 days) than control (14.56 4.73 days). By week 24, Psoriasis Area Severity Index (PASI) scores demonstrated substantial reduction group, decreasing from 26.98 11.28 2.48 3.01, whereas 25.82 10.47 10.40 7.63. overall rate was higher no cases ineffectiveness, 20.99% ineffectiveness group. Furthermore, there recurrence disease 11.11% rate. Both groups had similar incidence adverse reactions, indicating addition does not increase risk events. Discussion These findings suggest offers effective treatment option without compromising safety. However, larger-scale clinical trials are necessary validate these establish long-term benefits safety this approach diverse patient populations.

Language: Английский

Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)

Journal of Dermatological Treatment, Journal Year: 2024, Volume and Issue: 35(1)

Published: May 22, 2024

Background The recent introduction of biological drugs specifically targeting the interleukins involved in psoriasis pathogenesis revolutionized therapeutic scenario moderate to severe forms psoriasis. Among these, risankizumab, an anti-IL-23, was shown be effective both clinical trials and real-life experiences. However, data on its use very psoriasis, defined by a Psoriasis Area Severity Index (PASI) at least 30, are scant. In this context, our study aimed investigate outcomes patients with involvement difficult-to-treat areas treated risankizumab for up 2 years.

Language: Английский

Prescribing Pattern and Safety Profile of Biological Agents for Psoriasis in Real-World Practice: A Four-Year Calabrian Pharmacovigilance Analysis

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(10), P. 1329 - 1329

Published: Oct. 14, 2024

The treatment of psoriasis has made considerable progress with biologicals, including tumor necrosis factor inhibitors, and recently, monoclonal antibodies inhibiting directly interleukin (IL) 17, IL-23, or both IL-12/23. Newer biologicals are directed to the pathway appear improve complete near-complete clearance. newer have also been shown an excellent safety profile. However, despite experience patients having confirmed results obtained in clinical trials, there still few data on using biologicals.

Language: Английский